Biogen (BIIB) PT Raised to $321 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
Biogen (BIIB) Risk/Reward is Upside Biased - Stifel
October 13, 2022 11:06 AM EDTBiogen (NASDAQ: BIIB) shares were upgraded to Buy from Hold, with the price target raised to $299 from $223 per share by Stifel analyst Paul Matteis on Thursday.
Matteis said the company's shares have faded since the positive lecanemab data. In addition, they do worry... More
